en
Scientific article
Open access
English

Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium

Published inClinical Pharmacology and Therapeutics, vol. 108, no. 5, p. 1067-1077
Publication date2020
Abstract

Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel pharmacodynamics and clinical response. A genomewide association study (GWAS) was performed using DNA from 2,750 European ancestry individuals, using adenosine diphosphate-induced platelet reactivity and major cardiovascular and cerebrovascular events as outcome parameters. GWAS for platelet reactivity revealed a strong signal for CYP2C19*2 (P value = 1.67e-33). After correction for CYP2C19*2 no other single-nucleotide polymorphism reached genomewide significance. GWAS for a combined clinical end point of cardiovascular death, myocardial infarction, or stroke (5.0% event rate), or a combined end point of cardiovascular death or myocardial infarction (4.7% event rate) showed no significant results, although in coronary artery disease, percutaneous coronary intervention, and acute coronary syndrome subgroups, mutations in SCOS5P1, CDC42BPA, and CTRAC1 showed genomewide significance (lowest P values: 1.07e-09, 4.53e-08, and 2.60e-10, respectively). CYP2C19*2 is the strongest genetic determinant of on-clopidogrel platelet reactivity. We identified three novel associations in clinical outcome subgroups, suggestive for each of these outcomes.

Keywords
  • Aged
  • Blood Platelets/drug effects/metabolism
  • Cardiovascular Diseases/blood/genetics/mortality/prevention & control
  • Clopidogrel/adverse effects/therapeutic use
  • Coronary Artery Disease/mortality/therapy
  • Cytochrome P-450 CYP2C19/genetics/metabolism
  • Female
  • Genome-Wide Association Study
  • Humans
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention/adverse effects/mortality
  • Pharmacogenetics
  • Pharmacogenomic Variants
  • Platelet Aggregation Inhibitors/adverse effects/therapeutic use
  • Polymorphism, Single Nucleotide
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome
Citation (ISO format)
VERMA, Shefali Setia et al. Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. In: Clinical Pharmacology and Therapeutics, 2020, vol. 108, n° 5, p. 1067–1077. doi: 10.1002/cpt.1911
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal0009-9236
100views
44downloads

Technical informations

Creation07/16/2021 3:17:00 PM
First validation07/16/2021 3:17:00 PM
Update time03/16/2023 1:30:10 AM
Status update03/16/2023 1:30:06 AM
Last indexation02/12/2024 1:31:12 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack